Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
GXAI
Gaxos.ai
Sponsored
content by Gaxos.ai
JO
Jolt_Communications
Community Contributor
Gaxos.ai: Early-Stage AI Innovator in Gaming & Health
Key Takeaways Dual AI focus – Gaxos.ai builds AI-powered tools for game developers (via Unity integrations) and AI-driven health services under its RNK Health brand. First signs of commercial traction – After years of development, the company reported ~$24k in H1 2025 revenue, mainly from wellness pilot programs.
View narrative
US$2.21
FV
6.8% undervalued
intrinsic discount
119.00%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
7
users have followed this narrative
New
narrative
Microsoft
PI
PicaCoder
Community Contributor
After the AI Party: A Sobering Look at Microsoft's Future
The world has been captivated by the artificial intelligence boom, and no company has ridden the wave of investor enthusiasm quite like Microsoft. Buoyed by its strategic partnership with OpenAI and the integration of AI across its product ecosystem, the company's valuation has soared to unprecedented heights.
View narrative
US$500.00
FV
2.0% overvalued
intrinsic discount
6.75%
Revenue growth p.a.
Set Fair Value
8
users have liked this narrative
1
users have commented on this narrative
16
users have followed this narrative
8 days ago
author updated this narrative
Amazon.com
ZW
Zwfis
Community Contributor
Amazon's Future Rises as Stock Price Falls: A Long-Term Investment Vision
Amazon is a stock I am very interested in right now especially with the recent price drops that it has been experiencing since its 2Q25 results. A summary of Amazon as stated by Fiscal.ai: "Amazon.com, Inc.
View narrative
US$234.75
FV
2.9% undervalued
intrinsic discount
13.60%
Revenue growth p.a.
Set Fair Value
9
users have liked this narrative
2
users have commented on this narrative
13
users have followed this narrative
New
narrative
Verve Group
TI
TibiT
Community Contributor
Verve Group: A Tale of Three Futures
Verve Group stands at a critical juncture. After a history of explosive growth, the company has been hit by significant operational headwinds, primarily the difficult and costly migration to a unified technology platform and unfavorable currency exchange rates.
View narrative
€4.02
FV
47.4% undervalued
intrinsic discount
8.50%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
Updated
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Nazara Technologies
AN
AnalystConsensusTarget
Consensus Narrative from 10 Analysts
Regulatory Hurdles And Global Competition Will Test Gaming Expansion
Key Takeaways Heightened competition, regulatory challenges, and reliance on external platforms threaten Nazara's growth prospects and profitability sustainability. Heavy investment in esports and gamified learning is not yielding consistent profitability, with limited progress on global expansion and margin improvement.
View narrative
₹1.25k
FV
11.8% overvalued
intrinsic discount
17.25%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
Updated
narrative
Pacira BioSciences
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Policy Changes And Partnerships Will Expand Ambulatory Market Reach
Key Takeaways Increased adoption of non-opioid solutions and expanded outpatient procedure coverage are expected to drive sustained revenue growth for the company. Strategic partnerships, manufacturing efficiencies, and clinical pipeline progress support margin improvement and innovation-driven expansion into new markets.
View narrative
US$29.00
FV
13.1% undervalued
intrinsic discount
8.79%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
11
users have followed this narrative
Updated
narrative
Apollo Hospitals Enterprise
AN
AnalystConsensusTarget
Consensus Narrative from 29 Analysts
700 New Beds And Digital Health Will Reshape Healthcare Delivery
Key Takeaways Strategic expansion into new geographies, digital health growth, and specialty services enhance revenue, diversify risk, and strengthen profitability. Business integration, operational synergies, and improved insurance coverage drive margin gains, earnings stability, and future financial performance.
View narrative
₹8.59k
FV
8.9% undervalued
intrinsic discount
18.23%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
1
users have commented on this narrative
13
users have followed this narrative
Updated
narrative
Agenus
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Advanced Immuno-Oncology Therapies Will Reshape Future Cancer Care
Key Takeaways Strong clinical data and regulatory momentum could accelerate product approvals, drive significant market expansion, and improve near-term and long-term earnings potential. Strategic non-dilutive transactions and operational efficiencies bolster financial stability, enabling sustained R&D investment and enhancing margins and profitability prospects.
View narrative
US$12.33
FV
63.3% undervalued
intrinsic discount
8.01%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
11
users have followed this narrative
Updated
narrative
Ventia Services Group
AN
AnalystConsensusTarget
Consensus Narrative from 9 Analysts
New Contracts With Telstra And Defense Will Provide Future Revenue Stability
Key Takeaways Strategic contract wins, including with Telstra and in firefighting, improve revenue stability and visibility into future earnings growth. Diversification across sectors and focus on high-margin infrastructure services position Ventia well for sustained growth and stronger EBITDA margins.
View narrative
AU$5.27
FV
3.0% overvalued
intrinsic discount
5.78%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
10
users have followed this narrative
Updated
narrative
Verrica Pharmaceuticals
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
In-office Dermatology Access And Global Trials Will Shape Markets
Key Takeaways Expanding demand for non-invasive dermatology treatments and broadening pharmacy access are driving revenue growth and improved margins for Verrica. Advancing clinical pipeline and strategic partnerships support future revenue streams with minimal shareholder dilution and greater operating efficiency.
View narrative
US$15.00
FV
59.7% undervalued
intrinsic discount
107.12%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
Updated
narrative
KORE Group Holdings
AN
AnalystLowTarget
Consensus Narrative from 2 Analysts
Falling ARPU Will Pressure Margins Though IoT Adoption Will Rise
Key Takeaways Declining revenue per user and heavy reliance on lower-value contracts may hinder top-line growth despite expanding IoT demand. Dependence on few suppliers and increasing regulatory burdens expose the company to supply chain and compliance risks, impacting profitability.
View narrative
US$3.00
FV
29.0% undervalued
intrinsic discount
5.45%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Outset Medical
AN
AnalystLowTarget
Consensus Narrative from 4 Analysts
US Dialysis Pricing Pressure Will Hamper Prospects Despite Emerging Positivity
Key Takeaways Heavy reliance on a single flagship device risks revenue and margin stability if competition, regulatory issues, or market shifts occur. Growth opportunities from healthcare consumerization and recurring revenue face challenges from tighter reimbursement, capital intensity, and evolving at-home treatment models.
View narrative
US$17.00
FV
21.5% undervalued
intrinsic discount
9.67%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
New
narrative
Beachbody Company
AN
AnalystLowTarget
Consensus Narrative from 2 Analysts
Digital Fitness Pressures And Regulatory Costs Will Erode Value
Key Takeaways Persistent subscriber churn and heightened competition from tech giants are expected to reduce revenue growth and erode Beachbody's pricing power and earnings prospects. Rising regulatory compliance costs and commoditization in digital fitness threaten Beachbody's profitability, subscriber retention, and differentiation in an oversaturated market.
View narrative
US$4.00
FV
33.0% overvalued
intrinsic discount
-26.19%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Value any company in seconds
Popular companies